Navigation Links
Combining Therapies can Improve Survival for Early-stage Breast Cancer Patients

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen//. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not rece iving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients’ ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Source-Eurekalert
ME/B
'"/>




Related medicine news :

1. Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid
2. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
3. Preventive Therapies Found to be More Effective in Managing Migraines
4. Ayurvedic Therapies Cashing In On Medical Tourism
5. Immune-Boosting Therapies Of No Use In Preventing Miscarriage
6. Non Hormonal Therapies for Menopause Not Proved to be Effective
7. Need for More Talking Therapies for Treating Depression
8. Are Alternative Therapies A Reliable Alternative?
9. Special Behavioral Therapies made Women more likely to Attempt Suicide
10. Anti-Retroviral Therapies Associated with Reduced Infections in HIV-Infected Children
11. Alternative Therapies May Not Ease Menopause Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Anxiety of older ... the start of Medicare Part D a decade ago, according to The Senior ... older adults on how they are coping with rapidly rising costs. “The implications ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Face and Body Specialists are delighted to welcome a new addition to their ... Face and Body Specialists as a nurse practitioner performing cosmetic procedures ...
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when most ... of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison ... are cast aside. , That’s why one of her first decisions when her IAAM ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Inc. (NASDAQ: MSON ), an international surgical ... therapeutic ultrasonic products for spine surgery, skull-based surgery, ... other surgical applications, today announced financial results for ... fiscal year 2016 ended December 31, 2015. ... Highlights for the second quarter and first half ...
(Date:2/9/2016)... 2016 QGEN ; ... Abschluss eines Kooperationsvertrags mit 10x Genomics für ... den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und Bioinformatik ... Prime Standard: QIA) gab heute den Abschluss ... Entwicklung und Förderung umfassender Lösungen in den ...
(Date:2/9/2016)... Feb. 9, 2016   AllCare Plus Pharmacy ... Gold Seal of Approval ® for Home ... performance standards. The Gold Seal of Approval ® ... commitment to providing safe and effective care.  ... Pharmacy underwent a rigorous on-site survey in January 2016. ...
Breaking Medicine Technology: